SinoMab Bioscience Ltd. (HK:3681)
:3681
Top Page
SinoMab Bioscience Ltd.
(3681)
Select Model
Select Model
Rating:45Neutral
Price Target:
HK$1.50
▲(7.91% Upside)
Action:ReiteratedDate:11/22/25
SinoMab Bioscience Ltd. has a challenging financial outlook with persistent losses and high financial leverage. The technical indicators suggest a bearish trend, and the valuation metrics highlight ongoing profitability issues. These factors collectively result in a low overall stock score.
Positive Factors
Specialized biologics R&D focus
A concentrated business model around monoclonal antibodies gives SinoMab durable expertise and platform leverage in biologics discovery and development. Specialization supports repeatable R&D processes, potential modular reuse of tech and clearer go-to-market positioning in autoimmune and inflammatory niches.
Negative Factors
High financial leverage
A debt-to-equity ratio of 2.5 indicates material leverage that raises refinancing and interest-service risks. High leverage constrains strategic flexibility, increases cash burn pressure, and makes funding R&D or clinical programs more dependent on capital markets or dilutive financing, a lasting operational constraint.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized biologics R&D focus
A concentrated business model around monoclonal antibodies gives SinoMab durable expertise and platform leverage in biologics discovery and development. Specialization supports repeatable R&D processes, potential modular reuse of tech and clearer go-to-market positioning in autoimmune and inflammatory niches.
Read all positive factors
SinoMab Bioscience Ltd. (3681) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.42B
Dividend YieldN/A
Average Volume (3M)6.26M
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue Growth-100.00%
EPS Growth30.68%
CountryHK
Employees95
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding1,386,638,300
10 Day Avg. Volume8,278,616
30 Day Avg. Volume6,255,789
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)5.70
Price to Sales (P/S)542.51
P/FCF Ratio-6.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.21
Revenue Forecast (FY)HK$8.71M
SinoMab Bioscience Ltd. Business Overview & Revenue Model
Company Description
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its ...
How the Company Makes Money
SinoMab Bioscience generates revenue primarily through the commercialization of its biopharmaceutical products, including sales of its monoclonal antibody therapies upon gaining regulatory approval and entering the market. Additionally, the compan...
SinoMab Bioscience Ltd. Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -4.05M | 2.03M | 1.36M | 4.03M | 26.66M | 12.76M |
| Gross Profit | -4.05M | 543.00K | 422.00K | 4.03M | 26.66M | 12.76M |
| EBITDA | -116.76M | -142.79M | -200.46M | -244.29M | -296.43M | -158.61M |
| Net Income | -144.34M | -185.14M | -243.11M | -284.16M | -288.19M | -122.60M |
Balance Sheet | ||||||
| Total Assets | 722.09M | 753.10M | 847.79M | 1.01B | 1.04B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 143.10M | 106.88M | 234.66M | 376.19M | 589.53M | 916.20M |
| Total Debt | 408.11M | 482.27M | 450.81M | 357.18M | 275.46M | 97.84M |
| Total Liabilities | 478.80M | 560.19M | 552.20M | 498.77M | 361.43M | 142.51M |
| Stockholders Equity | 243.29M | 192.91M | 295.58M | 509.57M | 680.23M | 987.01M |
Cash Flow | ||||||
| Free Cash Flow | -59.02M | -172.30M | -237.74M | -413.29M | -345.30M | -217.29M |
| Operating Cash Flow | -87.12M | -130.80M | -133.85M | -300.54M | -147.06M | -141.34M |
| Investing Cash Flow | 17.14M | -94.48M | -96.92M | -81.36M | -137.70M | -179.22M |
| Financing Cash Flow | 18.09M | 73.27M | 82.27M | 102.28M | 57.52M | -18.81M |
SinoMab Bioscience Ltd. Technical Analysis
Positive
1.39
Price Trends
1.74
Positive
1.64
Positive
1.96
Negative
Market Momentum
-0.02
Positive
48.69
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3681, the sentiment is Positive. The current price of 1.39 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 1.74, and below the 200-day MA of 1.96, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 48.69 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3681.
SinoMab Bioscience Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | HK$27.73B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
65 Neutral | HK$83.77B | 51.47 | 32.32% | ― | 46.14% | 39.56% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.58B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
45 Neutral | HK$2.42B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
44 Neutral | HK$1.96B | -3.21 | -184.99% | ― | ― | -18.99% | |
40 Underperform | HK$11.43B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:3681
SinoMab Bioscience Ltd.
1.76
0.59
50.43%
HK:9995
RemeGen Co. Ltd. Class H
115.20
93.60
433.33%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.70
108.04%
HK:2157
Lepu Biopharma Co. Ltd. Class H
6.15
2.89
88.65%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.10
-2.90
-41.43%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.60
49.85
186.36%
SinoMab Bioscience Ltd. Corporate Events
SinoMab’s SM17 IND Application for IBD Accepted by NMPA
Dec 11, 2025
SinoMab BioScience Limited announced that its Investigational New Drug application for SM17, targeting Inflammatory Bowel Disease (IBD), has been accepted by China’s National Medical Products Administration. This development marks a signific...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.